Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].

Perry R, Kipps C, Martín MES, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L, Froelich L

Open source

DOI: 10.1016/j.tjpad.2026.100527
Published: 2026 Apr
Container: The journal of prevention of Alzheimer's disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2026.100527,
  title = {Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].},
  author = {Perry R and Kipps C and Martín MES and Bozzali M and Logroscino G and Trafford S and Dhadda S and Kanekiyo M and Goodwin A and Hodgkinson M and Hersch S and Irizarry M and Kramer L and Froelich L},
  year = {2026},
  journal = {The journal of prevention of Alzheimer's disease},
  doi = {10.1016/j.tjpad.2026.100527},
  url = {https://doi.org/10.1016/j.tjpad.2026.100527}
}

RIS

TY  - JOUR
TI  - Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].
AU  - Perry R
AU  - Kipps C
AU  - Martín MES
AU  - Bozzali M
AU  - Logroscino G
AU  - Trafford S
AU  - Dhadda S
AU  - Kanekiyo M
AU  - Goodwin A
AU  - Hodgkinson M
AU  - Hersch S
AU  - Irizarry M
AU  - Kramer L
AU  - Froelich L
PY  - 2026
JO  - The journal of prevention of Alzheimer's disease
DO  - 10.1016/j.tjpad.2026.100527
UR  - https://doi.org/10.1016/j.tjpad.2026.100527
ER  -

APA

R, P., C, K., MES, M., M, B., G, L., S, T., S, D., M, K., A, G., M, H., S, H., M, I., L, K., & L, F. (2026). Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2026.100527

Source records

pubmed · retrieved 2026-09-25T12:33:50.031Z